IMMUNITYBIO, INC. Research and Development Expense
IMMUNITYBIO, INC. (IBRX) reported Research and Development Expense of $190.14 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-03-03
- IMMUNITYBIO, INC. research and development expense for the quarter ending 2024-12-31 was $35.22M, a 31.65% decline year-over-year.
- IMMUNITYBIO, INC. research and development expense for the quarter ending 2024-09-30 was $50.44M, a 4.22% increase year-over-year.
- IMMUNITYBIO, INC. research and development expense for the quarter ending 2024-06-30 was $51.13M, a 3.84% decline year-over-year.
- IMMUNITYBIO, INC. research and development expense for the quarter ending 2024-03-31 was $53.35M, a 32.69% decline year-over-year.
- IMMUNITYBIO, INC. research and development expense for fiscal 2024 was $190.14M, a 18.17% decline from fiscal 2023.
- IMMUNITYBIO, INC. research and development expense for fiscal 2023 was $232.37M, a 6.36% decline from fiscal 2022.
- IMMUNITYBIO, INC. research and development expense for fiscal 2022 was $248.15M, a 26.63% increase from fiscal 2021.
- IMMUNITYBIO, INC. research and development expense for fiscal 2021 was $195.96M, a 40.46% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $35.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $85.66M derived: sum of 2 quarters · filed 2025-03-03 | $136.79M derived: sum of 3 quarters · filed 2025-03-03 | $190.14M 10-K · filed 2025-03-03 | ||||
| 2024-09-30 | $50.44M 10-Q · filed 2024-11-12 | $101.57M derived: sum of 2 quarters · filed 2024-11-12 | $154.92M 10-Q · filed 2024-11-12 | $206.46M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2024-06-30 | $51.13M 10-Q · filed 2024-08-12 | $104.48M 10-Q · filed 2024-08-12 | $156.01M derived: sum of 3 quarters · filed 2025-03-03 | $204.41M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2024-03-31 | $53.35M 10-Q · filed 2024-05-09 | $104.88M derived: sum of 2 quarters · filed 2025-03-03 | $153.28M derived: sum of 3 quarters · filed 2025-03-03 | $206.45M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-12-31 | $51.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $99.93M derived: sum of 2 quarters · filed 2025-03-03 | $153.10M derived: sum of 3 quarters · filed 2025-03-03 | $232.37M 10-K · filed 2025-03-03 | ||||
| 2023-09-30 | $48.40M 10-Q · filed 2024-11-12 | $101.57M derived: sum of 2 quarters · filed 2024-11-12 | $180.83M 10-Q · filed 2024-11-12 | $238.91M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | $53.17M 10-Q · filed 2024-08-12 | $132.43M 10-Q · filed 2024-08-12 | $190.51M derived: sum of 3 quarters · filed 2025-03-03 | $262.12M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $79.26M 10-Q · filed 2024-05-09 | $137.34M derived: sum of 2 quarters · filed 2025-03-03 | $208.95M derived: sum of 3 quarters · filed 2025-03-03 | $272.04M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $58.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $129.69M derived: sum of 2 quarters · filed 2025-03-03 | $192.77M derived: sum of 3 quarters · filed 2025-03-03 | $248.15M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $71.61M 10-Q · filed 2023-11-09 | $134.69M derived: sum of 2 quarters · filed 2023-11-09 | $190.07M 10-Q · filed 2023-11-09 | $241.82M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | $63.08M 10-Q · filed 2023-08-08 | $118.46M 10-Q · filed 2023-08-08 | $170.21M derived: sum of 3 quarters · filed 2024-03-19 | $219.49M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | $55.38M 10-Q · filed 2023-05-11 | $107.13M derived: sum of 2 quarters · filed 2024-03-19 | $156.41M derived: sum of 3 quarters · filed 2024-03-19 | $210.21M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | $51.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $101.03M derived: sum of 2 quarters · filed 2024-03-19 | $154.83M derived: sum of 3 quarters · filed 2024-03-19 | $195.96M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | $49.28M 10-Q · filed 2022-11-09 | $103.08M derived: sum of 2 quarters · filed 2022-11-09 | $144.21M 10-Q · filed 2022-11-09 | $187.56M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-06-30 | $53.80M 10-Q · filed 2022-08-08 | $94.93M 10-Q · filed 2022-08-08 | $138.28M derived: sum of 3 quarters · filed 2024-03-19 | $174.06M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-03-31 | $41.13M 10-K · filed 2024-03-19 | $84.48M derived: sum of 2 quarters · filed 2024-03-19 | $120.26M derived: sum of 3 quarters · filed 2024-03-19 | $153.26M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2020-12-31 | $43.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $79.13M derived: sum of 2 quarters · filed 2023-03-01 | $112.13M derived: sum of 3 quarters · filed 2023-03-01 | $139.51M 10-K · filed 2023-03-01 | $64.48M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $35.77M 10-Q · filed 2021-11-12 | $17.28M 10-Q · filed 2020-11-09 | $68.78M derived: sum of 2 quarters · filed 2021-11-12 | $96.15M 10-Q · filed 2021-11-12 | $44.23M 10-Q · filed 2020-11-09 | $170.37M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $33.01M 10-Q · filed 2021-08-12 | $13.71M 10-Q · filed 2020-08-07 | $60.38M 10-Q · filed 2021-08-12 | $26.94M 10-Q · filed 2020-08-07 | $134.59M derived: sum of 3 quarters · filed 2022-03-01 | $146.65M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $27.37M 10-Q · filed 2021-05-14 | $13.23M 10-Q · filed 2020-05-11 | $101.59M derived: sum of 2 quarters · filed 2022-03-01 | $113.64M derived: sum of 3 quarters · filed 2022-03-01 | $126.77M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $74.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $86.27M derived: sum of 2 quarters · filed 2022-03-01 | $99.40M derived: sum of 3 quarters · filed 2022-03-01 | $112.00M 10-K · filed 2022-03-01 | $49.78M 10-K · filed 2020-03-25 | |||
| 2019-09-30 | $12.05M 10-Q · filed 2020-11-09 | $25.18M derived: sum of 2 quarters · filed 2020-11-09 | $37.78M 10-Q · filed 2020-11-09 | $50.26M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | $13.13M 10-Q · filed 2020-08-07 | $25.73M 10-Q · filed 2020-08-07 | $38.21M derived: sum of 3 quarters · filed 2021-03-04 | $52.77M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | $12.60M 10-Q · filed 2020-05-11 | $25.08M derived: sum of 2 quarters · filed 2021-03-04 | $39.64M derived: sum of 3 quarters · filed 2021-03-04 | $54.33M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2018-12-31 | $12.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $27.04M derived: sum of 2 quarters · filed 2021-03-04 | $41.73M derived: sum of 3 quarters · filed 2021-03-04 | $55.72M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | $14.56M 10-Q · filed 2019-11-05 | $29.25M derived: sum of 2 quarters · filed 2019-11-05 | $43.24M 10-Q · filed 2019-11-05 | $55.26M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-06-30 | $14.69M 10-Q · filed 2019-08-06 | $28.68M 10-Q · filed 2019-08-06 | $40.70M derived: sum of 3 quarters · filed 2020-03-25 | $51.77M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-03-31 | $13.99M 10-Q · filed 2019-05-08 | $26.01M derived: sum of 2 quarters · filed 2020-03-25 | $37.08M derived: sum of 3 quarters · filed 2020-03-25 | $46.79M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2017-12-31 | $12.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $23.09M derived: sum of 2 quarters · filed 2020-03-25 | $32.80M derived: sum of 3 quarters · filed 2020-03-25 | $42.04M 10-K · filed 2020-03-25 | ||||
| 2017-09-30 | $11.07M 10-Q · filed 2018-11-07 | $20.77M derived: sum of 2 quarters · filed 2018-11-07 | $30.02M 10-Q · filed 2018-11-07 | $39.47M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-06-30 | $9.71M 10-Q · filed 2018-08-06 | $18.95M 10-Q · filed 2018-08-06 | $28.40M derived: sum of 3 quarters · filed 2019-03-13 | $36.76M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-03-31 | $9.25M 10-Q · filed 2018-05-07 | $18.69M derived: sum of 2 quarters · filed 2019-03-13 | $27.06M derived: sum of 3 quarters · filed 2019-03-13 | $33.45M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2016-12-31 | $9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $17.81M derived: sum of 2 quarters · filed 2019-03-13 | $24.20M derived: sum of 3 quarters · filed 2019-03-13 | $29.15M 10-K · filed 2019-03-13 | ||||
| 2016-09-30 | $8.36M 10-Q · filed 2017-11-07 | $14.75M derived: sum of 2 quarters · filed 2017-11-07 | $19.71M 10-Q · filed 2017-11-07 | $23.78M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-06-30 | $6.39M 10-Q · filed 2017-08-07 | $11.34M 10-Q · filed 2017-08-07 | $15.41M derived: sum of 3 quarters · filed 2018-03-12 | $20.07M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | $4.96M 10-Q · filed 2017-05-08 | $4.94M 10-Q · filed 2016-05-16 | $9.03M derived: sum of 2 quarters · filed 2018-03-12 | $13.68M derived: sum of 3 quarters · filed 2018-03-12 | $15.76M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2015-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $8.73M derived: sum of 2 quarters · filed 2018-03-12 | $10.80M derived: sum of 3 quarters · filed 2018-03-12 | $11.43M 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | $4.66M 10-Q · filed 2016-11-10 | $3.95M 10-Q · filed 2015-11-12 | $6.73M derived: sum of 2 quarters · filed 2016-11-10 | $7.36M 10-Q · filed 2016-11-10 | $6.33M 10-Q · filed 2015-11-12 | $8.24M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-06-30 | $2.07M 10-Q · filed 2016-08-15 | $1.75M 10-Q · filed 2015-09-10 | $2.68M 10-Q · filed 2016-08-15 | $2.35M 10-Q · filed 2015-09-10 | $3.58M derived: sum of 3 quarters · filed 2017-03-15 | $3.91M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-03-31 | $603.00K 10-Q · filed 2016-05-16 | $1.51M derived: sum of 2 quarters · filed 2017-03-15 | $1.83M derived: sum of 3 quarters · filed 2017-03-15 | $2.08M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2014-12-31 | $904.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $1.23M derived: sum of 2 quarters · filed 2017-03-15 | $1.48M derived: sum of 3 quarters · filed 2017-03-15 | $1.59M 10-K · filed 2017-03-15 | ||||
| 2014-09-30 | $328.00K 10-Q · filed 2015-11-12 | $571.00K derived: sum of 2 quarters · filed 2015-11-12 | $691.00K 10-Q · filed 2015-11-12 | |||||
| 2014-06-30 | $243.00K 10-Q · filed 2015-09-10 | $363.00K 10-Q · filed 2015-09-10 | ||||||
| 2013-12-31 | $446.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |